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Over 20 years ago single clonal deletions were the ﬁrst mitochondrial DNA (mtDNA) genetic defects described in association with
human disease. Since then very large numbers of children and adults harbouring such deletions have been described and it is clear
they are an important cause of human mitochondrial disease. However, there still remain many important challenges in relation to
our understanding of mechanisms leading to deletion formation and propagation and in relation to the factors determining the complex
and varying relationship between genotype and clinical phenotype. Although multidisciplinary team care is essential and can improve
quality of life and outcomes for patients, a deﬁnitive molecular treatment for single mtDNA deletions remains an important translational
research goal. Patients with mtDNA deletions exhibit a very wide range of diﬀerent clinical phenotypes with marked variation in age at
onset and disease severity. Single mtDNA deletions may enter into the diﬀerential diagnosis of many diﬀerent paediatric and adult
presentations across a wide range of medical specialties, although neurological presentations are amongst the most common. In this
review, we examine the molecular mechanisms underpinning mtDNA replication and we consider the hypotheses proposed to explain
the formation and propagation of single large-scale mtDNA deletions. We also describe the range of clinical features associated with
single mtDNA deletions, outline a molecular diagnostic approach and discuss current management including the role of aerobic and
resistance exercise training programmes.
 2012 Elsevier B.V. All rights reserved.
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Mitochondria are double membrane-bound intracellular
organelles that form large branching reticular networks
inside all eukaryotic cells except erythrocytes. Their pri-
mary function is to convert food substrates in the presence
of oxygen to energy, in the form of ATP, by aerobic0960-8966/$ - see front matter  2012 Elsevier B.V. All rights reserved.
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E-mail address: m.hanna@ucl.ac.uk (M.G. Hanna).respiration. This oxidative phosphorylation (OXPHOS)
reaction is performed in the mitochondrial inner membrane
by ﬁve enzyme complexes (so-called complexes I, II, III, IV
and V). Electrons are provided by NADH and FADH2,
which are reducing agents supplied by the oxidation of car-
bohydrates and fatty acids via the Krebs cycle and b-oxida-
tion, respectively. Electrons are passed between a series of
donors and increasingly electronegative acceptors until the
ﬁnal reduction of oxygen to water. Each step releases energy
which is used to actively pump protons (via complex I, III
and IV) from within the mitochondrial matrix into the
intermembrane space, thereby creating an electrochemical
gradient (Dwm) across the inner mitochondrial membrane
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oxygen species (ROS) and these molecules have long since
been implicated in a number of disease states and ageing
[2–4]. The proton gradient enables the terminal OXPHOS
enzyme, complex V (ATP synthase), to generate ATP from
ADP and inorganic phosphate, by allowing protons to ﬂow
passively through it along the electrochemical gradient back
into the mitochondrial matrix.
Mitochondria are unique amongst intracellular organ-
elles in that they contain their own DNA [5,6]. The mito-
chondrial genome is a double-stranded circular structure
consisting of 16,659 base-pairs (bp). Genes are located on
both strands; the so-called heavy (H) and light (L) strands
due to their relative composition of either mainly purines
(adenine and guanine) or pyrimidines (thymine and cyto-
sine), respectively, with the former having greater molecu-
lar weight than the latter. Mitochondrial DNA (mtDNA)
is highly compact with no introns and only one major
non-coding region (NCR), known as the control region
(consisting of 900 bp in mammals), which contains the
origin of replication for the H-strand (OH), the origins of
transcription for both H- and L-strands and the Displace-
ment loop (D-loop). The D-loop is a triple-stranded region
whose third strand (or 7S DNA) spans approximately
650 bp from nucleotide numbers 16,111 to 191 [7]. MtDNA
codes for 37 genes which enable synthesis of 13 OXPHOS
subunits required for aerobic respiration. The mtDNA is
susceptible to oxidative DNA damage due to its close
proximity to ROS at the inner mitochondrial membrane,
lack of protective histone proteins, and limited mitochon-
drial DNA proof-reading and repair systems. As a result,
mtDNA has a mutation rate 10–20 times that of nDNA
[8,9].
In vivo, nuclear DNA (nDNA) adopts a condensed
structure associated with histones and other proteins
[10,11] called nucleosomes which form the basic repeating
units of eukaryotic chromatin. These protein–DNA com-
plexes compact, order, and protect the DNA, and create
a degree of regulatory control to ensure its correct expres-
sion. They also facilitate co-ordinated copying and segrega-
tion of DNA molecules. MtDNA is also packaged as
protein–DNA complexes called nucleoids, which may be
the units of mtDNA transmission and inheritance [12,13].
Each mitochondrial nucleoid appears to contain a single
mtDNA molecule. Nucleoids are associated with the inner
mitochondrial membrane and are evenly spaced along the
mitochondrial reticulum [14–17]. Interestingly, the nucle-
oid distribution process appears to be reliant on protein–
protein interactions and is independent from the DNA
itself [18]. More than 25 nucleoid-interacting proteins have
been identiﬁed, but their precise role in mtDNA mainte-
nance is not fully established. In fact, many of these
proteins appear to have functions unrelated to mtDNA
maintenance suggesting they are bifunctional [18]. Some
are important for packaging, division and sorting of nucle-
oids, whereas others are involved in mtDNA replication,
repair and transcription [17]. A detailed review ofmitochondrial nucleoid-associated proteins and their func-
tion is given elsewhere [19].
Although the mtDNA encodes 13 essential OXPHOS
subunits, all other proteins needed for mitochondrial
OXPHOS function are encoded by nuclear genes. These
include the remaining 77 OXPHOS subunits, and proteins
involved with transcription and translation of mtDNA,
assembly of the OXPHOS enzyme complexes, biosynthesis
of mobile electron carriers in the inner mitochondrial mem-
brane, import of solutes and proteins into the mitochon-
drion, regulation of mitochondrial membrane dynamics
and composition, and mitochondrial ﬁssion and fusion.
More than 80 nuclear genes have already been linked to
human mitochondrial disease; however, an estimated
1500 nuclear-encoded proteins are targeted to mitochon-
dria [20]. Defects in any of these genes could theoretically
cause a mitochondrial disorder.
Single large-scale deletions of mtDNA were the ﬁrst
mtDNA genetic defects to be described and associated with
human mitochondrial disorders [21]. In 1988 Holt et al.
identiﬁed a deleted mtDNA subpopulation in skeletal mus-
cle but not blood in nine patients with mitochondrial
myopathy. They found that the deleted population coex-
isted with wild-type (WT) mtDNA in muscle, a state
known as heteroplasmy. It has subsequently been shown
that such single deletions account for a quarter of all adult
patients with mtDNA-related disease [22]; data consistent
with the authors’ own clinical practice (unpublished data).
They are also an important cause of paediatric mtDNA-
related mitochondrial disease. Single mtDNA deletions
are considered sporadic events with low inheritance risk,
whereas multiple mtDNA deletions are the result of pri-
mary nuclear defects in genes responsible for mtDNA
maintenance or nucleoside metabolism and follow Mende-
lian inheritance patterns [23].
Here we review current understanding of the molecular
mechanisms underlying single large-scale mtDNA deletion
formation. We will also consider the clinical phenotypes,
diagnostic work-up and management of this subgroup of
mitochondrial disorders.
2. Mitochondrial DNA replication
mtDNA encodes only 13 of the 90 essential OXPHOS
subunits. The remaining subunits, along with all the
proteins required for their transcription, translation,
post-translational modiﬁcation and assembly, are nuclear-
encoded. The nuclear encoded proteins include those essen-
tial for mtDNA maintenance and repair.
Accurate mtDNA replication is essential to maintain the
Dwm electrochemical potential, established across the inner
mitochondrial membrane by respiration, and is necessary
for energy production in the form of ATP. Although the
mtDNA replication machinery is nuclear-encoded, it is
completely separate from its nuclear counterpart, and con-
sists of just 4 basic enzyme components: DNA polymerase
gamma (POLc); DNA helicase Twinkle; mitochondrial
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chondrial RNA polymerase (POLRMT). Unlike nuclear
DNA which replicates once during cell division, mtDNA
replicates continuously throughout the cell cycle in dividing
and post-mitotic cells.
Although the replication apparatus is relatively well
characterised, the precise mode of mtDNA replication
has been intensely debated [24–26]. For many years
mtDNA replication was thought to occur exclusively by a
strand-displacement model, where a leading strand is syn-
thesised from OH and a lagging strand from the origin of
L-strand replication (OL) in an asymmetric and unidirec-
tional pattern [27–30]. In 2000, Holt et al. proposed an
alternative model in which leading- and lagging-strand syn-
theses were coupled (so-called synchronous or coupled rep-
lication), on the basis of Brewer and Fangman 2D-agarose
gel electrophoresis (2D-AGE) [31]. The strand-coupled
mechanism was suggested to initiate simultaneously in
both directions from a broad zone, OriZ [32]. Later studies
demonstrated that some replication intermediates were
RNase H-sensitive, which led to the assumption that they
were derived from ribonucleotide-rich DNA synthesis initi-
ated unidirectionally from the non-coding region [33–35].
According to this replication mode, referred to as the ribo-
nucleotide incorporation throughout the lagging strand
(RITOLS) model, the lagging strand is initially laid down
as RNA before being converted to DNA. In a similar man-
ner to the strand-displacement model, RITOLS predicts
delayed lagging strand DNA synthesis. Although the pre-
cise mode of mtDNA replication is contentious, the weight
of experimental data in support of all three models makes
their combined existence likely.
3. Molecular mechanisms underlying formation and timing of
single mitochondrial DNA deletions
Most deletions (85%) occur within the major arc
between OH and OL and are ﬂanked by runs of direct
homologous base-pair repeats. It is generally considered
that mtDNA deletions arise during replication through
slipped-strand mispairing between direct homologous
base-pairs (Fig. 1A–D) [36]. This mechanism assumes the
asynchronous strand displacement model of mtDNA repli-
cation, since it is reliant on the presence of long stretches of
single-stranded DNA which do not exist in the coupled and
RITOLS replication models. During replication a single
stranded repeat of the H-strand misanneals with a newly
exposed L-strand repeat (Fig. 1C). This forms a down-
stream loop of single-stranded parental H-strand which is
degraded, with subsequent ligation of the free H-strands
and continued replication. The end result is one WT and
one deleted mtDNA molecule (Fig. 1D). A recent alterna-
tive hypothesis proposed that deletions form during repair
of mtDNA at double-stranded breaks, rather than during
replication [37]. During repair of a double-stranded break
(a commonly occurring transition state needed to restore
the replication fork after a stalling event) single-strandedregions are generated by exonuclease activity. The single
strands would be free to anneal with microhomologous
sequences [38]. Subsequent repair, ligation and degradation
of the exposed single strands would lead to mtDNA mole-
cules with a deleted portion. Krishnan et al. suggest that if
deletion formation only occurs during replication, higher
levels of deleted molecules should be present in mitotic
rather than post-mitotic cells (where mtDNA replication
is less frequent); however, this has been shown not to be
the case in rapidly dividing colonic tissue [39]. The
slipped-strand model also predicts conservation of the 30
repeat sequence in the deleted daughter molecule, which
does not always occur [40,41].
Uncertainty surrounding the pathophysiological mecha-
nism underlying deletion formation in mtDNA includes the
precise timing of the deletional event itself, which may
occur during early embryonic development [42,43] or
oogenesis [37]. Deleted species have been demonstrated in
tissue of mesodermal (skeletal muscle) and ectodermal
(brain) origin, suggesting that the deletion is likely to occur
prior to diﬀerentiation of these two embryonic layers [43].
However, single large-scale mtDNA deletions have also
been shown to exist in the oocyte prior to fertilisation
[44,45]. In the case of progressive external ophthalmoplegia
(PEO), where muscle is the only tissue clinically involved,
the deletion may arise later in development, for example
during diﬀerentiation of the muscle precursor cells. An ear-
lier deletion event during germ cell maturation followed by
mitotic segregation of the mutant mtDNA might also
explain the tissue-speciﬁc phenotype of this disorder [46].
The case for deletion formation during germline matura-
tion is compelling. Human oocytes contain around 100,000
mtDNA molecules [44]. It is estimated that half of mature
oocytes in healthy women each contain 5–20 molecules
with the same “common” 4977 bp mtDNA deletion found
in patients with mtDNA deletion disorders [44,47,48].
Chinnery et al. have hypothesised that the inherited dele-
tion arises in the grandmother’s oocyte [46]. As mtDNA
is maintained in a mature oocyte for many years without
replicating, Krishnan et al. [37] suggested that the original
mtDNA deletion event occurs in the grandmother’s oocyte
during repair of damaged mtDNA rather than during
mtDNA replication. The lack of any correlation between
increasing age of the maternal grandmother and risk of
having a grandchild with a single mtDNA deletion disor-
der, however, does not appear to support this hypothesis
[49]. So, if an oocyte containing deleted mtDNA molecules
due to aberrant replication or repair from the maternal
grandmother is fertilised, the zygote is destined to become
the unaﬀected mother, and it is possible a proportion of
primordial germ cells contain low levels of deleted
mtDNA. The deleted mtDNA levels must, however, reach
a critical biochemical threshold for disease to develop in
the grandchild.
This rapid shift of mtDNA heteroplasmy between gener-
ations is attributed to the so-called genetic bottleneck the-
ory of mtDNA transmission [50]. Although the precise
Fig. 1. Diagram illustrating the consensus slipped-strand model of mitochondrial DNA deletion formation (adapted from Shoﬀner et al. [36]). (A) A
mitochondrial DNA (mtDNA) molecule prior to replication containing two direct homologous base-pair (bp) repeats (a/a1 and b/b1). The origin of heavy
strand (OH) and light strand (OL) replication are shown. (B) Replication of the mtDNA is initiated at OH. During replication the daughter heavy strand
(brown arrow) uses the parent light strand as a template, thereby displacing the parent heavy stand. (C) The ﬁrst direct homologous bp repeat on the
parent heavy strand (a) misanneals with the second newly exposed direct bp repeat on the parent light strand (b1), forming a downstream loop of heavy
strand. The single-stranded downstream loop is susceptible to damage and is subsequently degraded until double-stranded DNA is reached, with loss of
the second parent heavy strand bp repeat (b). The free ends of the parent heavy strand are then ligated and replication of the daughter heavy strand
continues. When heavy strand synthesis reaches OL (two-thirds around the circumference of the mtDNA molecule), replication of the daughter light
strand begins using the parent heavy strand as a template, in the opposite direction. As such, mtDNA replication occurs in an asynchronous manner. (D)
Slipped-strand replication results in the synthesis of one wild-type (consisting of the parent light strand and the daughter heavy strand) and one deleted
(consisting of the parent heavy strand and the daughter light strand) mtDNA molecule.
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in the literature, there are currently three main biological
mechanisms that might potentially explain the phenome-
non: (1) ampliﬁcation of a reduced number of mtDNA
molecules during early embryonic primordial germ cell
development (approximately 7–9 days post-fertilisation)
[51]; (2) selective replication and transmission of a subpop-
ulation of mtDNA molecules at a later stage of develop-
ment during post-natal oocyte maturation [52]; (3)
segregation of identical heteroplasmic mtDNA molecules
thereby forming homoplasmic units, with eﬀective restric-
tion on the pool available for mtDNA transmission with-
out any signiﬁcant reduction in mtDNA content in the
germ cells [53,54].
If a deleted mtDNA molecule or homoplasmic deleted
unit is selected for clonal expansion after the bottleneck,
an accumulation of abnormally high levels of deleted
mtDNA molecules might occur in a small number ofmature oocytes in the unaﬀected mother. This would pre-
dict a 5/100,000 risk of oﬀspring inheriting high levels of
the pathogenic mtDNA deletion, which roughly corre-
sponds to the incidence of mtDNA deletion disorders in
the general population [22]. Clinically unaﬀected mothers
are very unlikely to have more than one aﬀected child.
However, there is an estimated 4% risk of subsequent
transmission from an aﬀected woman [46].
4. Size and location of single mitochondrial DNA deletions
The size and location of large-scale deletions may vary.
However, one third of patients harbour a common 4977 bp
mtDNA deletion [44,47,48]. The deleted molecule exists as
a single species and is heteroplasmic, with variable mutant
levels detectable in diﬀerent tissues. The majority of dele-
tions arise within the long arc between OH and OL but
retain these replication sites. The likely explanation for this
Table 1
Clinical syndromes and associated features of single mtDNA deletion
disorders.
Reference
Clinical syndromes associated with single mtDNA deletions
Pearson marrow-pancreas syndrome [62–64]
Kearns–Sayre syndrome [76–80]
Progressive external ophthalmoplegia [109]
Isolated anaemia ± lactic acidosis [65,70]
Pancreatic exocrine insuﬃciency without marrow
involvement
[72]
Pancytopaenia and tubulopathy [73]
Tubulopathy and hypoparathyroidism ± encephalopathy [74,75]
Mitochondrial myopathy, encephalopathy, lactic acidosis
and stroke-like episodes
[110]
Myoclonic epilepsy with ragged red ﬁbres [111]
Leigh syndrome [66–68]
Diabetes and deafness [112]
Other clinical features associated with single mtDNA deletionsa
Myopathy [109]
Endocrinopathy: multiple endocrine disturbance;
hypoparathyroidism; Addison’s disease; adrenal
insuﬃciency; short stature
[113–116]
Gastrointestinal disturbance: constipation; diarrhoea;
pseudo-obstruction; cyclical vomiting; gastro-
oesophageal reﬂux
[116,117]
Organic acidopathy [116,118]
Seizures [116]
Cardiomyopathy and cardiac conduction defects [69,117,119]
Neuropsychiatric symptoms and dementia [120]
a These may occur in isolation, but are more usually seen in the context
of an early-onset multisystem disorder.
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the deleted molecules must retain the ability to replicate.
The deletion removes a variable number of essential pro-
tein-encoding subunits for complexes I, III, IV and V and
tRNA-encoding genes required for translation of the
mtDNA-encoded OXPHOS complexes, with resulting dys-
function in OXPHOS.
Early work found no correlation between clinical sever-
ity and the type, size or location of the large-scale rear-
rangement [55]. However, Yamashita et al. reported that
a larger deleted segment, and consequently a greater num-
ber of deleted tRNAs, correlated with an earlier age of dis-
ease onset. Patients with large numbers of deleted tRNAs
also appear to be more likely to develop Kearns–Sayre syn-
drome (KSS), suggesting that the quality of the deletion is
somehow linked either to the development of the KSS phe-
notype or increased propensity for multi-systemic involve-
ment [56]. Since patients with the same “common” deletion
show diﬀerent clinical symptoms, other factors are postu-
lated to contribute to the observed phenotypic heterogene-
ity, such as systemic distribution and mutant load of
deleted mtDNA molecules. The time-point at which the
deletion arises has also been suggested to determine the
aﬀected tissues, clinical phenotype, percentage and location
of the deletion [57].
Despite the probable importance of deletion size and
location, many other factors are likely to contribute to
the varied clinical phenotype and severity seen in this
patient group. Deletions are heteroplasmic and mutant
load may vary between tissue types and can shift over time.
This may explain the clinical features (dependent on the tis-
sue with the greatest energy demand and level of mutant
mtDNA) and delayed onset that is sometimes seen in
patients with the disease. Random mitotic segregation of
mutant and WT mtDNA molecules, relaxed replication,
tissue-speciﬁc energy requirements, contrasting selection
bias of mitotic and post-mitotic cells, together with the
mtDNA and nuclear haplotypes, are all thought to inﬂu-
ence the ultimate spectrum of disease. There is marked tis-
sue speciﬁcity seen with mtDNA deletions when compared
with other mtDNA mutations [58–61]. This observation,
taken together with ongoing research examining the role
the mitochondrial nucleoid plays in mtDNA distribution,
is likely to be important in unravelling the cause of extreme
tissue segregation seen in mtDNA deletion disorders.
5. Clinical phenotypes associated with single mitochondrial
DNA deletions
Three sporadic clinical syndromes are classically associ-
ated with large-scale deletions of mtDNA. However, it is
increasingly recognised that there is a continuum of clinical
phenotypes associated with single mtDNA deletions, and a
large number of variants exist. The less common pheno-
types associated with single mtDNA deletions are summa-
rised in Table 1, but for purposes of this review we will
describe each of the classical phenotypes in detail.5.1. Pearson marrow-pancreas syndrome (PMPS)
This is a severe and often rapidly fatal disorder of
infancy/early childhood characterised by sideroblastic
anaemia and variable involvement of other blood cells,
together with exocrine pancreatic dysfunction. Onset is
usually in early infancy with transfusion-dependent side-
roblastic anaemia, neutropaenia, thrombocytopenia or
pancytopaenia, poor growth and lactic acidosis. Pancreatic
dysfunction may be present at disease onset or it may
develop later. Other clinical features include an enteropa-
thy that may need parenteral nutrition support, and severe
renal tubulopathy. Bone marrow examination typically
reveals high levels of ringed sideroblasts and vacuolisation
of myeloid precursors [62–64]. The disorder is frequently
fatal in early childhood because of overwhelming lactic aci-
dosis or liver failure. It is estimated that one out of three
neonatal cases of PMPS surviving infancy develop features
compatible with Kearns–Sayre syndrome (KSS) [65],
including cardiac conduction defects, sensorineural hearing
loss, pigmentary retinopathy and progressive neurological
impairment which can sometimes resemble Leigh syn-
drome [66–69]. In PMPS deleted mtDNA molecules are
usually present at higher levels in blood than other tissues;
hence haematological manifestations are such a prominent
feature of the syndrome. Due to the high replication rate of
blood cells, mtDNA deletions can be cleared from these
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manifestations (for example, the need for transfusions has
usually resolved by 2 years). In contrast, deleted mtDNA
molecules tend to progressively accumulate in other tissues
(especially non-dividing tissues), leading to the multisystem
and relentlessly progressive nature of this disorder. Despite
the classical description of PMPS, however, it is important
to be aware of the more atypical presentations. Neonates
can present with anaemia as the only onset symptom in
one third of cases [65,70], and hepatopathy may be the
most prominent feature [71]. The diagnosis should also
be considered when there is isolated pancreatic exocrine
insuﬃciency without marrow involvement [72]. Pancyto-
paenia and tubulopathy can occur without exocrine pan-
creatic dysfunction [73], and there are case reports of
milder, childhood onset, isolated tubulopathy and hypo-
parathyroidism [74], which has also been reported in asso-
ciation with recurrent encephalopathy [75].
5.2. Kearns–Sayre syndrome (KSS)
KSS is a multisystem disorder deﬁned clinically by the
triad of PEO and pigmentary retinopathy with onset before
the age of 20 years plus at least one of: cardiac conduction
block; cerebrospinal ﬂuid (CSF) protein concentration
greater than 0.1 g/L; cerebellar ataxia [76–80]. Frequent
additional signs include sensorineural hearing loss, renal
tubular acidosis, dementia, seizures, short stature and endo-
crine disturbance (diabetes mellitus, hypoparathyroidism
and growth hormone deﬁciency). A progressive skeletal
myopathy is also frequently seen. The most common mag-
netic resonance imaging (MRI) ﬁndings are cerebral and
cerebellar atrophy with bilateral, often symmetrical, hyper-
intense lesions in the subcortical white matter, thalamus,
basal ganglia and brainstem [81–83]. Interestingly, there
appears to be little correlation between neurological deﬁcits
and the severity of the MRI features [84]. KSS is most com-
monly associated with single large-scale deletions of
mtDNA [56]. We recently identiﬁed a case of KSS caused
by nuclear genomic dysfunction due to mutations in
RRM2B in a patient with multiple deletions of the mtDNA
[85]. It is, therefore, possible for KSS to follow a Mendelian
pattern of inheritance, although the majority of cases are
sporadic.
5.3. Progressive external ophthalmoplegia (PEO)
PEO is considered the mildest of the three syndromes
most commonly associated with single mtDNA deletions.
It is characterised by slowly progressive bilateral ptosis
and limitation of eye movements (often with reduced
upgaze early in the disease process) secondary to extra-ocu-
lar muscle (EOM) weakness. There is often no diplopia as
the ophthalmoparesis is bilateral, relatively symmetrical,
and has gradual onset. Additional clinical features may
include oropharyngeal dysfunction causing dysphagia,
proximal limb weakness and exercise intolerance. IsolatedPEO is usually associated with a normal lifespan. The rea-
son for selective involvement of the EOMs in the single
deletion disorders is not understood. It may relate to dis-
tinct structural, functional, biochemical and immunologi-
cal properties of this muscle group compared to other
skeletal muscles [86]. The EOMs have also been reported
to have a lower biochemical threshold for COX deﬁciency
than limb muscles [87].
6. Investigations and diagnosis of single mitochondrial DNA
deletion disorders
Table 1 outlines the potentially wide range of diﬀerent
clinical settings in which mitochondrial disease caused by
single deletions of mtDNA enters into the diﬀerential diag-
nosis. The diagnosis of single mtDNA deletion disorders
involves careful clinical assessment and tailored investiga-
tions that are often guided by the age of the patient.
6.1. Mitochondrial DNA analysis
Children, unlike adults, often have single large-scale
rearrangements detectable in blood, and muscle biopsy is
seldom required. In PMPS the mtDNA deletions are usu-
ally present at higher levels in blood than other tissues, so
diagnosis is reliably made using leucocyte mtDNA. The
deleted mtDNA molecules are selectively shed from the
rapidly dividing leucocytes with increasing age [88–91].
The consequence is that the deleted mtDNA molecules
are often undetectable in blood by early adolescence.
Deleted mtDNA molecules, however, appear more readily
detectable in cells extracted from urine, and a diagnosis
can occasionally be achieved by analysing mtDNA from
uroepithelial cells (extracted from 30 to 50 mls of urine).
Unfortunately, in contrast to the m.3243A > G point muta-
tion, where uroepithelial cell mutant levels have been shown
to closely resemble mutant levels present in muscle tissue
[92], urine levels of mtDNA deletions are not always repre-
sentative of the most clinically aﬀected tissues [93]. As a
consequence, a diagnostic muscle biopsy is still often ulti-
mately required. MtDNA is analysed using long-range
polymerase chain reaction (PCR) and Southern blot genetic
techniques to demonstrate large-scale rearrangements (dele-
tions and/or duplications) of the mitochondrial genome.
6.2. Muscle histochemical analysis
The muscle tissue itself can be examined using light
microscopy for features that support the diagnosis of mito-
chondrial disease. These include subsarcolemmal mitochon-
drial accumulation demonstrated on routine histochemical
staining as “ragged-red ﬁbres” (RRF) in the modiﬁed
Gomori trichrome stain, or as succinate dehydrogenase
(SDH)-positive ﬁbres. Cytochrome c oxidase (COX) stain-
ing may reveal ﬁbres deﬁcient in complex IV, and is
particularly useful when combined with sequential SDH
staining since COX-deﬁcient SDH-positive ﬁbres appear
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are a common and expected ﬁnding in patients with single
mtDNA deletions.
6.3. Respiratory chain enzymology
Biochemical analysis of the respiratory chain enzymes
can be performed on fresh muscle by measuring substrate
oxidation using polarography. Speciﬁc enzyme activities
can also be measured using spectrophotometric assays
using either fresh muscle or muscle immediately frozen in
liquid nitrogen or isopentane and stored at 80 C. Single
mtDNA deletions usually involve several genes, including
at least one tRNA, so that global mitochondrial protein
synthesis is aﬀected. As a result, activities of OXPHOS
complexes containing mtDNA-encoded subunits (com-
plexes I, III, IV and V) can potentially be reduced [94].
However, normal OXPHOS enzyme activities may be
observed in the muscle of patients with single mtDNA dele-
tions; therefore, genetic analysis should be performed if
there is clinical suspicion of a single mtDNA disorder,
regardless of the biochemical ﬁndings.
7. Management of single mitochondrial DNA deletion
disorders
This review does not provide a comprehensive discus-
sion of all current treatment regimens for mitochondrial
disorders; these may be found in detail elsewhere [94–96].
The following is a summary of treatment strategies aimed
speciﬁcally at patients with single mtDNA deletions.
7.1. Importance of multidisciplinary team care to optimise
quality of life and improve outcomes
Since no curative therapy currently exists for patients
with mitochondrial disease, symptom management is criti-
cal to maintain quality of life. Awareness of potential dis-
ease complications allows early intervention, thereby
reducing morbidly and mortality. All patients require sup-
port from a dedicated multidisciplinary team to facilitate
careful consideration of both medical and non-medical
needs.
Clinical issues related to single mtDNA deletion disor-
ders require input from doctors with specialist expertise
in mitochondrial disorders. Patients with PMPS typically
present during childhood to paediatricians and need sup-
portive measures, including regular blood transfusions,
pancreatic enzyme replacement, fat-soluble vitamin sup-
plementation, hormone replacement for endocrine dis-
ease, and enteral feeding. Epilepsy, movement disorders
and neuromuscular disease are common manifestations
of mitochondrial disease in later life. As a consequence,
patients usually present to the neurologist during adult-
hood. Ophthalmic review is often necessary to assess
and monitor retinopathy, exclude cataracts, and provide
prosthetic lid props or perform surgery for severe ptosis.A cardiology opinion is mandatory even if cardiac symp-
toms are absent. This is particularly important in
patients with KSS in whom cardiac conduction defects
are common and a permanent pacemaker or implantable
deﬁbrillator may be required. Audiological assessment
for aids and cochlear implants for hearing loss, and
referral to endocrinology, gastroenterology, renal or
palliative care may all be appropriate. Finally, advice
should be sought prior to general anaesthesia so that
perioperative complications related to cardiac arrhythmia
and administration of potentially mitotoxic agents are
avoided.
A specialist mitochondrial disease nurse is crucial and
provides the patient with a point of contact so that medical
needs are addressed between out-patient clinic appoint-
ments. They also oﬀer invaluable practical advice concern-
ing available social and income support. Speech and
language therapy and dietetic review are required if there
is bulbar involvement or problems surrounding adequate
nutrition, and occupational therapy, physiotherapy and
orthotics can maintain and improve mobility to enable an
independent lifestyle.
7.2. Pharmacotherapy
Pharmacotherapy, including Co-enzyme Q10 (Ubiqui-
none), creatine and dichloroacetate have all been studied
in randomised controlled double-blind clinical trials of
patients with single mtDNA deletion disorders [97–101].
However, a Cochrane systematic review concluded there
was no clear evidence supporting their routine use in mito-
chondrial disease [102]. Cerebral folate deﬁciency can occur
in KSS [103,104], and signiﬁcant clinical improvement and
resolution of white matter changes on MRI have been
reported in patients with KSS treated with folinic acid
which, unlike folate, is able to cross the blood brain barrier
[105]. The frequency of cerebral folate deﬁciency in KSS is
unknown, but CSF measurement and folinic acid supple-
mentation should be considered, particularly when leuko-
encephalopathy is present.
7.3. Exercise therapy to reduce deleted mitochondrial DNA
molecules
Finally, exercise training has provided promising results
in patients with single mtDNA deletion disorders. Activa-
tion of muscle satellite cells by speciﬁc exercise training reg-
imens allows WT mtDNA to repopulate muscle tissue and
eﬀectively reduce mutant load below the biochemical
threshold needed to impair OXPHOS [106]. Endurance
exercise training has been shown to increase muscle aerobic
capacity [107], whilst resistance training improves muscle
strength and oxidative ability [108]. The merits of resis-
tance versus endurance exercise training are currently being
evaluated in patients with single mtDNA deletions, with
the aim of providing tailored exercise regimes suitable for
individual patients in the near future.
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Although single mtDNA deletions were the ﬁrst mtDNA
mutations associated with human disease [21], there are still
many unanswered questions surrounding their origin and
propagation. The variable clinical severity and heterogene-
ity of disease phenotype remains incompletely understood.
Single mtDNA deletion disorders continue to provide a
diagnostic challenge to paediatric and adult neurologists.
Although primarily sporadic, a Mendelian inheritance pat-
tern should not be used as an exclusion criterion for KSS,
especially in the context of multiple mtDNA deletions
[85]. Diagnosis is usually achieved using DNA extracted
from blood in children. However, use of uroepithelial cells
is increasingly being recognised as a non-invasive alterna-
tive to muscle biopsy, particularly in children with cardiac
conduction disorders in whom a general anaesthetic poses
signiﬁcant risks. Although treatment is primarily support-
ive, a multidisciplinary team complemented by a tailored
exercise regimen signiﬁcantly improves overall function
and life quality for patients and their families.
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